Naldemedine Tosylate (BioDeep_00000839835)
代谢物信息卡片
化学式: C39H42N4O9S (742.2672)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
InChI: /m1./s1
描述信息
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Ruichao Mao, Lihua Bie, Maofeng Xu, Xiaocong Wang, Jun Gao. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.
Physical chemistry chemical physics : PCCP.
2021 Jun; 23(22):12549-12558. doi:
10.1039/d1cp01045j. [PMID: 34008647] - Eri Hikita, Mituko Hashimoto, Takeo Yasu, Mikio Shirota, Kazuha Nakamura. Efficacy of Naldemedine in the Management of Constipation in a Patient with Severe COVID-19 Receiving Mechanical Ventilation.
Journal of palliative medicine.
2021 05; 24(5):651-652. doi:
10.1089/jpm.2021.0028. [PMID: 33544649] - Toshiyuki Kanemasa, Takanobu Matsuzaki, Katsumi Koike, Minoru Hasegawa, Tsutomu Suzuki. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Life sciences.
2020 Sep; 257(?):118048. doi:
10.1016/j.lfs.2020.118048. [PMID: 32622946] - Kazuya Fukumura, Nao Kawaguchi, Toru Ishibashi, Ryuji Kubota, Yukio Tada, Eriko Ogura. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Clinical drug investigation.
2020 Jun; 40(6):529-540. doi:
10.1007/s40261-020-00902-w. [PMID: 32323104] - Shuichi Ohnishi, Kazuya Fukumura, Ryuji Kubota, Toshihiro Wajima. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects.
Xenobiotica; the fate of foreign compounds in biological systems.
2019 Sep; 49(9):1044-1053. doi:
10.1080/00498254.2018.1536815. [PMID: 30351180] - Ryosuke Watari, Akihiro Matsuda, Shuichi Ohnishi, Hiroshi Hasegawa. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
Drug metabolism and pharmacokinetics.
2019 Apr; 34(2):126-133. doi:
10.1016/j.dmpk.2018.12.002. [PMID: 30770183] - Ryuji Kubota, Kazuya Fukumura, Toshihiro Wajima. Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine.
Pharmaceutical research.
2018 Oct; 35(11):225. doi:
10.1007/s11095-018-2501-7. [PMID: 30280262] - Kazuya Fukumura, Takaaki Yokota, Yuko Baba, Juan Camilo Arjona Ferreira. Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers.
Clinical pharmacology in drug development.
2018 06; 7(5):474-483. doi:
10.1002/cpdd.387. [PMID: 28960888]
